Myeloid neoplasms with t(5;12) and etv6-pdgfrb gene fusion: case report with imatinib therapy and review of the literature

摘要

Sequential therapy with low dose cytarabine and 6-mercap- topurine may be a safe and cost effective option for those JMML patients where HSCT is not feasible. Although it was not found to be effective in inducing complete clinical remission in most of the patients, it can induce prolonged control of disease and better quality of life in a subset of patients and serve as a bridge to HSCT.